Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2021 Annual Report, which is available under the Investor Documents & Presentations section of the Company’s website www.avacta.com.
The non-material presentation provided to shareholders can be found under the Investor Documents & Presentations section of the Company’s website www.avacta.com.